维普期刊资源整合服务平台（V6.5）

51篇 您的检索式：作者名="DIASIO RB"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy显示文摘	Diasio RB Lu Z	1994	J Clin Oncol1994，12，11：	1
2	Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics显示文摘	Mattison LK Soong R Diasio RB	2002	Pharmacogenomics2002，3，4：	1
3	Histone deacetylase inhibitors: current status and overview of recent clinical trials显示文摘	Ma X Ezzeldin HH Diasio RB	2009	Drugs2009，69，：	1
4	Dihydorpyrimidine deydorgenase activity and fluorouracil chemotherapy 显示文摘	Diasio RB Lu Z	1994	J Clin Oncol1994，12，11：	1
5	Edotecarin: a novel topoisomerase I inhibitor显示文摘	SAIF MW DIASIO RB	2005	Clin Colorectal Cancer2005，5，1：	1
6	Melabolism of pyrimidine ana- logues and their nueleosides显示文摘	Daher GC Harris BE Diasio RB	1990	Pharmacol Ther1990，48，2：	1
7	Capecitabine induces rapid, sustained response in two patients with extensive oral verrueous carcinoma显示文摘	Salesiotis A Soong R Diasio RB	2003	Clin Cancer Res2003，9，2：	1
8	Adenocarcinoma of the pancreas associated with hypoglycemia:case report and review of the literature显示文摘	Diasio RB Eanes RZ Chen ML		0，，：	1
9	Histone deacetylase inhibitors: current status and overview of recent clinical trials 显示文摘	Ma X Ezzeldin HH Diasio RB	2009	Drugs2009，69，14：	1
10	Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines显示文摘	Diasio RB	1999	Drugs1999，58，3：	1
11	The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil 显示文摘	Diasio RB Johnson MR	2000	Pharmacology2000，61，3：	1
12	The role of pharmaeogeneties and pharmacogenomics in cancer chemotherapy with fluorouracil 显示文摘	Diasio RB Johnson MR	2000	Pharmacology2000，61，3：	1
13	Histone deacetylase in- hibitors:current status and overview of recent clinical trials显示文摘	Ma X Ezzeldin HH Diasio RB	2009	Drugs2009，69，14：	1
14	Phase Ⅰ and pharmacological study of oral 5- fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inacti- vator eniluracil显示文摘	Baker SD Diasio RB OReilly S	2000	J Clin Oncol2000，4，：	1
15	Clinical pharmacology of 5-fluorouracil显示文摘	Diasio RB Harris BE	1989	Clin Pharmacokinet1989，16，4：	1
16	Clinical implications of dihydropyrimidine ehydrogenase inhibition显示文摘	Diasio RB	1999	Oncology(Williston Park)1999，，：	1
17	Implications of dihydropy- rimidine dehydrogenase on 5-fluorouracil pharmacogenet- cs and pharmacogenomics 显示文摘	Mattison LK Soong R Diasio RB	2002	Pharmacogenomics2002，3，4：	1
18	Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis显示文摘	STAMM AM DIASIO RB DISMUKES WE	1987	Am J Med1987，83，2：	1
19	Advances and challenges influo-ropyrimidine phannacogenomics and pharmacogenetics 显示文摘	Soong R Diasio RB	2005	Pharmacogenomics2005，6，8：	1
20	The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil显示文摘	Diasio RB Johnson MR	2000	Pharmacology2000，61，3：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示